The 5-Hydroxytryptamine Receptor 2A pipeline drugs market research report outlays comprehensive information on the 5-Hydroxytryptamine Receptor 2A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the 5-Hydroxytryptamine Receptor 2A pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Undisclosed, Metabolic Disorders, and Women’s Health which include the indications Unspecified Psychiatric Disorders, Schizophrenia, Unspecified, Obesity, Type 2 Diabetes, Post Partum Depression (Maternal Depression / Postnatal Depression), and Premenstrual Dysphoric Disorder (PMDD). It also reviews key players involved in 5-Hydroxytryptamine Receptor 2A targeted therapeutics development with respective active and dormant or discontinued products.
The 5-Hydroxytryptamine Receptor 2A pipeline targets constitutes close to 208 molecules. Out of which, approximately 198 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 2, 2, 16, 32, 35, 8, 74, and 25 respectively. Similarly, the universities portfolio in Phase II, Phase I, Preclinical, and Discovery comprises 3, 4, 1, and 2 molecule.
5-Hydroxytryptamine Receptor 2A overview
5-hydroxytryptamine receptor 2A (5-HT2A) is a G protein-coupled receptor (GPCR) that plays a role in a wide range of physiological and behavioral processes, including cognition, mood, perception, and sensory processing. 5-HT2A receptors are located throughout the central nervous system, as well as in peripheral tissues such as the cardiovascular system and the gastrointestinal tract.
For a complete picture of 5-Hydroxytryptamine Receptor 2A’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
